Toggle navigation
Home
Search
Services
Blog
Contact
About
Antibody-Drug Conjugate Therapy for Cancer Treatment
Chari, Ravi V.
Immunogen, Inc., Cambridge, MA, United States
Search 16 grants from Ravi Chari
Search grants from Immunogen, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
The Jackson Laboratory Center for Precision Genetics: From New Models to Novel Therapeutics
Conditional manipulation of hnRNPLL expression in murine models
Pediatric HIV-encephalopathy in DRC: effect of ART &role of compartmentalization
Atrial Natriuretic Peptide Na+Cl- Sensitive Hypertension
Cells and Extracellular Matrix in Pulmonary Hypertension
Recently added grants:
Social Network Analysis and Social Support Intervention for Rural Dwelling Older Adults with T2DM
IL-36 cytokines and gut immunity
Effects of Nutritional Ketosis on Brain Response to Hypoglycemia in People with Type One Diabetes Mellitus
Boston Speech Motor Control Symposium
Glycomic Modulation of Gut Microbiome During HIV Infection
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA056209-02A3
Application #
2008020
Study Section
Special Emphasis Panel (ZRG2-SSS-4 (02))
Project Start
1992-07-01
Project End
1999-03-31
Budget Start
1997-07-11
Budget End
1998-03-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Institution
Name
Immunogen, Inc.
Department
Type
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Related projects
NIH 1998
R44 CA
Antibody-Drug Conjugate Therapy for Cancer Treatment
Chari, Ravi V. / Immunogen, Inc.
NIH 1997
R44 CA
Antibody-Drug Conjugate Therapy for Cancer Treatment
Chari, Ravi V. / Immunogen, Inc.
Publications
Xie, Hongsheng; Audette, Charlene; Hoffee, Mary et al.
(2004)
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.
J Pharmacol Exp Ther 308:1073-82
Comments
Be the first to comment on this grant